MyomoMYO
MYO
About: Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Employees: 185
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
112% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 17
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
7% more funds holding
Funds holding: 71 [Q4 2024] → 76 (+5) [Q1 2025]
2.2% more ownership
Funds ownership: 44.19% [Q4 2024] → 46.39% (+2.2%) [Q1 2025]
12% less call options, than puts
Call options by funds: $224K | Put options by funds: $254K
19% less capital invested
Capital invested by funds: $94.6M [Q4 2024] → $76.7M (-$17.9M) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
257%
upside
Avg. target
$10.75
284%
upside
High target
$11.50
311%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 311%upside $11.50 | Buy Maintained | 5 Jun 2025 |
Craig-Hallum Craig Knickerbocker | 257%upside $10 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Myomo, Inc. (MYO) Q1 2025 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - Alliance Global Partners Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the Myomo's First Quarter 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
1 month ago
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.
Neutral
Business Wire
1 month ago
Myomo Reports First Quarter 2025 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was.
Neutral
Business Wire
1 month ago
Myomo to Host Investor & Analyst Day Event on June 18, 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth l.
Neutral
Business Wire
1 month ago
Myomo to Report First Quarter 2025 Financial Results on May 7
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive off.
Neutral
Business Wire
1 month ago
Myomo Launches the MyoPro® 2x
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers improved arm and hand function for individuals with upper-limb paralysis and neuromuscular conditions, today announced the launch of the MyoPro 2x, the latest evolution in its flagship MyoPro product line. Designed to enhance the user experience, the MyoPro 2x introduces a reimagined approach to donning, empowering users with a more intuitive, efficient, and consistent process t.
Neutral
Business Wire
2 months ago
Myomo Announces Upcoming Changes to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the board they will not stand for re-election as Class II directors. Ms. Knapp has been a director since July 2016 and Mr. Jacobovitz has served on Myomo's board since January 2.
Neutral
Business Wire
2 months ago
Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer and David Henry, chief financial officer, will present at the 24th Annual Needham Virtual Healthcare Conference, being held from April 7th to April 10th, and will be holding one-on-on.
Negative
Zacks Investment Research
3 months ago
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.07 per share a year ago.
Neutral
Seeking Alpha
3 months ago
Myomo, Inc. (MYO) Q4 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - AGP Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the Myomo Fourth Quarter 2024 Earnings Conference Call.
Charts implemented using Lightweight Charts™